Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives $20.25 Consensus PT from Brokerages

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has been given a consensus rating of “Buy” by the six analysts that are covering the stock, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $20.25.

A number of research firms have issued reports on ZVRA. HC Wainwright increased their price target on Zevra Therapeutics from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Monday, August 5th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zevra Therapeutics in a research report on Monday, August 5th.

Zevra Therapeutics Price Performance

ZVRA opened at $6.78 on Friday. The company has a current ratio of 2.10, a quick ratio of 2.10 and a debt-to-equity ratio of 0.88. The firm has a market cap of $283.76 million, a price-to-earnings ratio of -5.02 and a beta of 1.97. The stock’s 50-day moving average price is $5.50 and its 200 day moving average price is $5.49. Zevra Therapeutics has a 12-month low of $3.89 and a 12-month high of $8.44.

Insider Transactions at Zevra Therapeutics

In other Zevra Therapeutics news, Director John B. Bode bought 10,000 shares of the business’s stock in a transaction dated Friday, July 12th. The shares were acquired at an average price of $5.87 per share, with a total value of $58,700.00. Following the transaction, the director now owns 30,000 shares of the company’s stock, valued at $176,100. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. In the last 90 days, insiders have acquired 22,000 shares of company stock valued at $140,340. Corporate insiders own 2.40% of the company’s stock.

Institutional Investors Weigh In On Zevra Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. International Assets Investment Management LLC raised its position in shares of Zevra Therapeutics by 555.0% during the 4th quarter. International Assets Investment Management LLC now owns 6,550 shares of the company’s stock worth $43,000 after acquiring an additional 5,550 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in Zevra Therapeutics by 134.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 9,673 shares of the company’s stock worth $63,000 after buying an additional 5,545 shares during the last quarter. Price T Rowe Associates Inc. MD purchased a new position in Zevra Therapeutics during the 1st quarter worth approximately $64,000. IFG Advisors LLC grew its stake in Zevra Therapeutics by 45.0% during the 1st quarter. IFG Advisors LLC now owns 18,700 shares of the company’s stock worth $108,000 after buying an additional 5,800 shares during the last quarter. Finally, Strs Ohio grew its stake in Zevra Therapeutics by 151.9% during the 4th quarter. Strs Ohio now owns 19,400 shares of the company’s stock worth $127,000 after buying an additional 11,700 shares during the last quarter. Institutional investors and hedge funds own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.